[go: up one dir, main page]

NZ813695B2 - Parp1 inhibitors and uses thereof - Google Patents

Parp1 inhibitors and uses thereof Download PDF

Info

Publication number
NZ813695B2
NZ813695B2 NZ813695A NZ81369523A NZ813695B2 NZ 813695 B2 NZ813695 B2 NZ 813695B2 NZ 813695 A NZ813695 A NZ 813695A NZ 81369523 A NZ81369523 A NZ 81369523A NZ 813695 B2 NZ813695 B2 NZ 813695B2
Authority
NZ
New Zealand
Prior art keywords
pharmaceutically acceptable
compound
inhibitors
parp1 inhibitors
acceptable salt
Prior art date
Application number
NZ813695A
Other versions
NZ813695A (en
Inventor
Qing Dong
Robert L Hoffman
Stephen W Kaldor
Joseph Robert Pinchman
Lynnie Trzoss
Porino Jinjo Va
Original Assignee
Xinthera Inc
Filing date
Publication date
Application filed by Xinthera Inc filed Critical Xinthera Inc
Priority claimed from PCT/US2023/011268 external-priority patent/WO2023141290A1/en
Publication of NZ813695A publication Critical patent/NZ813695A/en
Publication of NZ813695B2 publication Critical patent/NZ813695B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Claims (5)

1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical ition sing a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
3. The compound of claim 1 that is or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 that is or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 that is or a pharmaceutically able salt thereof.
NZ813695A 2023-01-20 Parp1 inhibitors and uses thereof NZ813695B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263301907P 2022-01-21 2022-01-21
US202263376338P 2022-09-20 2022-09-20
PCT/US2023/011268 WO2023141290A1 (en) 2022-01-21 2023-01-20 Parp1 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
NZ813695A NZ813695A (en) 2024-10-25
NZ813695B2 true NZ813695B2 (en) 2025-01-28

Family

ID=

Similar Documents

Publication Publication Date Title
IL314009B1 (en) PARP1 inhibitors and their uses
EP4356975A3 (en) Erbb/btk inhibitors
IL311376B1 (en) Azetidine and pyrrolidine parp1 inhibitors and uses thereof
EP4620472A3 (en) Tricyclic parp1 inhibitors and uses thereof
MX2024000299A (en) Anti-viral compounds.
EP4410291A3 (en) Erbb receptor inhibitors
WO2022115381A8 (en) Compositions and methods for treating cns disorders
TN2022000092A1 (en) Oral complement factor d inhibitors
TN2022000255A1 (en) Pyrrolopyrimidine amines as complement inhibitors
WO2021016256A3 (en) Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors
CA3200722A1 (en) Heteroaryl-acetylenes, pharmaceutical compositions thereof, and their therapeutic applications
PH12021552513A1 (en) Pyrrole compounds
WO2003049690A3 (en) Hiv integrase inhibitors
MX2022009197A (en) Methods of treatment for alpha-1 antitrypsin deficiency.
TN2022000095A1 (en) Oral complement factor d inhibitors
PH12023552856A1 (en) Bicyclic heteroaromatic inhibitors of klk5
WO2022106902A8 (en) Benzenesulfonamide derivatives and uses thereof
MX2023009954A (en) Aminopyrimidine compounds and methods of their use.
CA2535210A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
WO2023129513A3 (en) Bicyclic heteroaromatic inhibitors of nicotinamide n-methyltransferase, and compositions and uses thereof
NZ813695B2 (en) Parp1 inhibitors and uses thereof
WO2023141522A3 (en) Multicyclic compounds
AU2024241125A1 (en) Nlrp3 inflammasome inhibitors and uses thereof
WO2024243304A3 (en) Bicyclic heteroaryl compounds
WO2024054661A3 (en) Dynamin activators